Pharminent

Janssen touts Xarelto’s broader uses, halts CV trial early

The blockbuster blood thinner has proven so effective at preventing heart attack and stroke in certain patients that a global phase 3 study is being stopped more than a year early. http://www.biopharmadive.com/news/janssen-touts-xareltos-broader-uses-halts-cv-trial-early/435852/

Filed under: Cardiovascular